Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 20/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21175476 | 0.85 | HDAC4 (0.76) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL21175471 | 0.84 | HDAC4 (0.67) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL20521278 | 0.80 | HDAC4 (0.65) | HDAC4HDAC6HDAC8HDAC1HDAC5 | |
| SCHEMBL21175482 | 0.80 | HDAC4 (0.71) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL21175514 | 0.79 | HDAC4 (0.79) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL19030803 | 0.78 | HDAC4 (0.76) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL14645710 | 0.78 | HDAC4 (1.00) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL14645583 | 0.77 | HDAC4 (1.00) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL23650745 | 0.77 | HDAC6 (0.64) | HDAC4HDAC6HDAC8HDAC2HDAC1 | |
| SCHEMBL23650765 | 0.77 | HDAC6 (0.61) | HDAC4HDAC6HDAC8HDAC2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653146-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-05-19 | — | — | US | disclosed |
| US-20190223442-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190223442-A1 | MICROBIOCIDAL OXADIAZOLE DERIVATIVES | NOX3, NOX1, MPO | HDAC4 1299/4885HDAC6 676/4885HDAC8 1669/4885 |
| US-10653146-B2 | Microbiocidal oxadiazole derivatives | NOX3, NOX1, MPO | HDAC4 1299/4885HDAC6 676/4885HDAC8 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.